KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Merck (MRK) Cost of Revenue (2016 - 2025)

Merck (MRK) has disclosed Cost of Revenue for 17 consecutive years, with $5.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 45.01% to $5.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $16.4 billion, a 7.83% increase, with the full-year FY2025 number at $16.4 billion, up 7.83% from a year prior.
  • Cost of Revenue was $5.6 billion for Q4 2025 at Merck, up from $3.9 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $5.6 billion in Q4 2025 to a low of $3.1 billion in Q2 2021.
  • A 5-year average of $3.9 billion and a median of $3.9 billion in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 68.18% in 2022, then dropped 27.03% in 2023.
  • Merck's Cost of Revenue stood at $3.9 billion in 2021, then rose by 0.18% to $3.9 billion in 2022, then increased by 0.8% to $3.9 billion in 2023, then dropped by 2.15% to $3.8 billion in 2024, then skyrocketed by 45.01% to $5.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Cost of Revenue are $5.6 billion (Q4 2025), $3.9 billion (Q3 2025), and $3.6 billion (Q2 2025).